NEWS
Notice Regarding Completion of Acquisition of
Olympus Group’s Norwalk, Ohio Medical Manufacturing Operation
November 4, 2020
Nissha Co., Ltd.
We hereby announce that Nissha Co., Ltd. (hereinafter, “Nissha”) ’s consolidated subsidiary, Nissha Medical Technologies (hereinafter, “NMT”), operating as the Medical Technologies Business Unit (MTBU) of Nissha, has acquired all assets of Olympus Group’s Norwalk, Ohio Medical Manufacturing Operation. This site currently manufacturers rigid scopes for urology and gynecology and other components of therapeutic devices.
This strategic acquisition provides value to all NMT OEM customers through increased vertical integration for our NMT Design and Manufacturing Division. This agreement further enhances NMT design services and manufacturing capabilities related to machined components, and increased production capacity in North America to support NMT global growth and operations.
The acquisition consists of the Norwalk, Ohio manufacturing operation, alongside an agreement to move additional production lines from other OSTA facilities into NMT facilities.
This strategic acquisition provides value to all NMT OEM customers through increased vertical integration for our NMT Design and Manufacturing Division. This agreement further enhances NMT design services and manufacturing capabilities related to machined components, and increased production capacity in North America to support NMT global growth and operations.
The acquisition consists of the Norwalk, Ohio manufacturing operation, alongside an agreement to move additional production lines from other OSTA facilities into NMT facilities.
Overview of Norwalk, Ohio Medical Manufacturing Operation
Location | Norwalk, Ohio; U.S.A. |
---|---|
Representative | Sam Heleba Senior Vice President, Nissha Co., Ltd. General Manager of Medical Technologies Business Unit Chief Executive Officer, Graphic Controls Holdings, Inc. d/b/a Nissha Medical Technologies |
Employees | 111 (as of the end of April 2020) |
Business outline | Manufacturing rigid scopes for urology and gynecology and components of therapeutic devices |
Net sales | Approximately 5.5 billion yen (forecast for FY2025) |
Outlook going forward
The impact of this transaction on the Company’s consolidated results for the current fiscal year is expected to be negligible. Going forward, if revisions to business forecasts or the announcement of other matters become necessary, we will make prompt disclosure of the same.
The content of the web is information at press time, may change thereafter without notice. Due to risks and uncertainties, predictions may differ from actual results. Please be forewarned.